RBC Capital Keeps Their Buy Rating on Elevance Health (ELV)
In a report released yesterday, Ben Hendrix from RBC Capital reiterated a Buy rating on Elevance Health (ELV – Research Report), with a price ...
Barclays: Attractive Valuation, Strategic Growth, and Robust Capital Returns Drive Buy Rating
Barclays (BARC) has received a new Buy rating, initiated by Bank of America Securities analyst, Rohith Chandrarajan.Stay Ahead of the ...
RBC upgrades JPMorgan stock target on strong Q4 results
RBC Capital Markets adjusted its outlook on shares of JPMorgan Chase & Co. (NYSE: NYSE:JPM) shares by increasing the price ...
RBC Capital cuts Intra-Cellular stock rating, hikes target to $132
RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...
MAA price target lowered to $158 from $165 at RBC Capital
RBC Capital analyst Brad Heffern lowered the firm’s price target on MAA (MAA) to $158 from $165 and keeps a Sector Perform rating on the shares. The firm updated residential real estate investment ...